Nemdatine (Memantine Hydrochloride)

Memantine Hydrochloride, the active ingredient in Nemdatine, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adult patients. GNH USA supplies Nemdatine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride is used in the management of neurodegenerative conditions that involve glutamate‑mediated excitotoxicity, primarily Alzheimer’s disease. - Alzheimer’s disease (moderate to severe): improves cognition and daily functioning. - Alzheimer’s disease (behavioral symptoms): may reduce agitation and aggression. - Alzheimer’s disease (maintenance therapy): helps sustain functional abilities over time.

Adverse reactions to Memantine Hydrochloride can vary in frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach with urge to vomit.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hallucinations or psychosis: visual or auditory disturbances. - Cardiac arrhythmia: irregular heart rhythm noted on monitoring.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Renal impairment: adjust dose or monitor renal function. - Hepatic disease: assess liver function and consider dose modification. - History of seizures: use with caution and observe for neurologic changes. - Concomitant CNS depressants: monitor for additive sedation. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neurotoxicity. - High‑dose zinc supplements: may reduce absorption of memantine.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefits. - CNS depressants (e.g., benzodiazepines): enhanced sedation risk. - Proton‑pump inhibitors: possible decrease in oral bioavailability.